Oxcia is a biopharmaceutical company that provides therapies and DNA damage response mechanisms to treat cancer and inflammatory diseases.
Oxcia has raised $2.9M in total funding. The most recent round was Grant. The last funding was announced in December 2025.
Oxcia's investors include European Innovation Council, Swelife, MedTech4Health.
Oxcia is headquartered in Stockholm, Sweden.
Oxcia is a biopharmaceutical company that provides therapies and DNA damage response mechanisms to treat cancer and inflammatory diseases.
Oxcia is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oxcia — Funding & Investors." VCBacked, December 29, 2025, https://www.vcbacked.co/company/oxcia. Accessed July 19, 2026.
VCBacked. (2025). Oxcia — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/oxcia
{{cite web |title=Oxcia — Funding & Investors |url=https://www.vcbacked.co/company/oxcia |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated